APO RESEARCH · REPORT
Bacteriophage
Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.
Product & engineering
Understand the product.
Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.
Selected research
Market Outlook & Growth Opportunities
Global Bacteriophage Market Outlook and Growth Opportunities 2026
Market perspective
Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.
The United States is the largest consumer market, accounting for about 38%, and Europe is the second largest market, accounting for about 26%.
The market for Bacteriophage is fragmented with players such as NPO Microgen, Proteon Pharmaceuticals, Phagelux, Intralytix, Micreos, Eliava BioPreparations, Locus Biosciences,Inc, Pharmex Group,LLC, Pherecydes Pharma, APS Biocontrol Ltd. (APS) , Qingdao Phagepharm Bio-tech,. Fixed-Phage Limited, Zeptometrix, Phage International, Inc., MicroMir, iNtODEWORLD, Inc., NEXTBIOTICS, Armata Pharmaceuticals, Inc., Innophage and so on. Among them, the top 5 manufacturers with about 34% revenue market share.
Read the full market overview
This report provides an overview of the global Bacteriophage market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Bacteriophage and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Bacteriophage revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Bacteriophage market.
Bacteriophage Segment by Company
NPO Microgen
Proteon Pharmaceuticals
Phagelux
Intralytix
Micreos
Eliava BioPreparations
Locus Biosciences,Inc
Pharmex Group,LLC
Pherecydes Pharma
APS Biocontrol Ltd. (APS)
Qingdao Phagepharm Bio-tech
Fixed-Phage Limited
Zeptometrix
Phage International, Inc.
MicroMir
iNtODEWORLD, Inc.
NEXTBIOTICS
Armata Pharmaceuticals, Inc.
Innophage
Adaptive Phage Therapeutics
TechnoPhage
Bacteriophage Segment by Type
DsDNA Bacteriophage
SsDNA Bacteriophage
SsRNA Bacteriophage
Others
Bacteriophage Segment by Application
Animal Health
Aquaculture
Agriculture
Food Industry
Human Health
Others
Bacteriophage Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Bacteriophage status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Bacteriophage key companies, revenue, market share, and recent developments.
3. To split the Bacteriophage breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Bacteriophage market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Bacteriophage significant trends, drivers, influence factors in global and regions.
6. To analyze Bacteriophage competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacteriophage market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bacteriophage and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bacteriophage.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bacteriophage industry.
Chapter 3: Detailed analysis of Bacteriophage company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Bacteriophage in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Bacteriophage in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- DsDNA Bacteriophage
- SsDNA Bacteriophage
- SsRNA Bacteriophage
- Others
Applications
- Animal Health
- Aquaculture
- Agriculture
- Food Industry
- Human Health
- Others
Companies covered
- NPO Microgen
- Proteon Pharmaceuticals
- Phagelux
- Intralytix
- Micreos
- Eliava BioPreparations
- Locus Biosciences,Inc
- Pharmex Group,LLC
- Pherecydes Pharma
- APS Biocontrol Ltd. (APS)
- Qingdao Phagepharm Bio-tech
- Fixed-Phage Limited
- Zeptometrix
- Phage International, Inc.
- MicroMir
- iNtODEWORLD, Inc.
- NEXTBIOTICS
- Armata Pharmaceuticals, Inc.
- Innophage
- Adaptive Phage Therapeutics
- TechnoPhage
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Bacteriophage Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Bacteriophage Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Bacteriophage Market Dynamics
- 2.1 Bacteriophage Industry Trends
- 2.2 Bacteriophage Industry Drivers
- 2.3 Bacteriophage Industry Opportunities and Challenges
- 2.4 Bacteriophage Industry Restraints
3 Bacteriophage Market by Company
- 3.1 Global Bacteriophage Company Revenue Ranking in 2025
- 3.2 Global Bacteriophage Revenue by Company (2021-2026)
- 3.3 Global Bacteriophage Company Ranking (2024-2026)
- 3.4 Global Bacteriophage Company Manufacturing Base and Headquarters
- 3.5 Global Bacteriophage Company Product Type and Application
- 3.6 Global Bacteriophage Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Bacteriophage Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Bacteriophage Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Bacteriophage Market by Type
- 4.1 Bacteriophage Type Introduction
- 4.1.1 DsDNA Bacteriophage
- 4.1.2 SsDNA Bacteriophage
- 4.1.3 SsRNA Bacteriophage
- 4.1.4 Others
- 4.2 Global Bacteriophage Sales Value by Type
- 4.2.1 Global Bacteriophage Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Bacteriophage Sales Value by Type (2021-2032)
- 4.2.3 Global Bacteriophage Sales Value Share by Type (2021-2032)
5 Bacteriophage Market by Application
- 5.1 Bacteriophage Application Introduction
- 5.1.1 Animal Health
- 5.1.2 Aquaculture
- 5.1.3 Agriculture
- 5.1.4 Food Industry
- 5.1.5 Human Health
- 5.1.6 Others
- 5.2 Global Bacteriophage Sales Value by Application
- 5.2.1 Global Bacteriophage Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Bacteriophage Sales Value by Application (2021-2032)
- 5.2.3 Global Bacteriophage Sales Value Share by Application (2021-2032)
6 Bacteriophage Regional Value Analysis
- 6.1 Global Bacteriophage Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Bacteriophage Sales Value by Region (2021-2032)
- 6.2.1 Global Bacteriophage Sales Value by Region: 2021-2026
- 6.2.2 Global Bacteriophage Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Bacteriophage Sales Value (2021-2032)
- 6.3.2 North America Bacteriophage Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Bacteriophage Sales Value (2021-2032)
- 6.4.2 Europe Bacteriophage Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Bacteriophage Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Bacteriophage Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Bacteriophage Sales Value (2021-2032)
- 6.6.2 South America Bacteriophage Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Bacteriophage Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Bacteriophage Sales Value Share by Country, 2025 VS 2032
7 Bacteriophage Country-level Value Analysis
- 7.1 Global Bacteriophage Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Bacteriophage Sales Value by Country (2021-2032)
- 7.2.1 Global Bacteriophage Sales Value by Country (2021-2026)
- 7.2.2 Global Bacteriophage Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.7.2 France Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.14.2 China Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.17.2 India Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Bacteriophage Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Bacteriophage Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Bacteriophage Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Bacteriophage Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 NPO Microgen
- 8.1.1 NPO Microgen Company Information
- 8.1.2 NPO Microgen Business Overview
- 8.1.3 NPO Microgen Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.1.4 NPO Microgen Bacteriophage Product Portfolio
- 8.1.5 NPO Microgen Recent Developments
- 8.2 Proteon Pharmaceuticals
- 8.2.1 Proteon Pharmaceuticals Company Information
- 8.2.2 Proteon Pharmaceuticals Business Overview
- 8.2.3 Proteon Pharmaceuticals Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.2.4 Proteon Pharmaceuticals Bacteriophage Product Portfolio
- 8.2.5 Proteon Pharmaceuticals Recent Developments
- 8.3 Phagelux
- 8.3.1 Phagelux Company Information
- 8.3.2 Phagelux Business Overview
- 8.3.3 Phagelux Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.3.4 Phagelux Bacteriophage Product Portfolio
- 8.3.5 Phagelux Recent Developments
- 8.4 Intralytix
- 8.4.1 Intralytix Company Information
- 8.4.2 Intralytix Business Overview
- 8.4.3 Intralytix Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.4.4 Intralytix Bacteriophage Product Portfolio
- 8.4.5 Intralytix Recent Developments
- 8.5 Micreos
- 8.5.1 Micreos Company Information
- 8.5.2 Micreos Business Overview
- 8.5.3 Micreos Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.5.4 Micreos Bacteriophage Product Portfolio
- 8.5.5 Micreos Recent Developments
- 8.6 Eliava BioPreparations
- 8.6.1 Eliava BioPreparations Company Information
- 8.6.2 Eliava BioPreparations Business Overview
- 8.6.3 Eliava BioPreparations Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.6.4 Eliava BioPreparations Bacteriophage Product Portfolio
- 8.6.5 Eliava BioPreparations Recent Developments
- 8.7 Locus Biosciences,Inc
- 8.7.1 Locus Biosciences,Inc Company Information
- 8.7.2 Locus Biosciences,Inc Business Overview
- 8.7.3 Locus Biosciences,Inc Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.7.4 Locus Biosciences,Inc Bacteriophage Product Portfolio
- 8.7.5 Locus Biosciences,Inc Recent Developments
- 8.8 Pharmex Group,LLC
- 8.8.1 Pharmex Group,LLC Company Information
- 8.8.2 Pharmex Group,LLC Business Overview
- 8.8.3 Pharmex Group,LLC Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.8.4 Pharmex Group,LLC Bacteriophage Product Portfolio
- 8.8.5 Pharmex Group,LLC Recent Developments
- 8.9 Pherecydes Pharma
- 8.9.1 Pherecydes Pharma Company Information
- 8.9.2 Pherecydes Pharma Business Overview
- 8.9.3 Pherecydes Pharma Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.9.4 Pherecydes Pharma Bacteriophage Product Portfolio
- 8.9.5 Pherecydes Pharma Recent Developments
- 8.10 APS Biocontrol Ltd. (APS)
- 8.10.1 APS Biocontrol Ltd. (APS) Company Information
- 8.10.2 APS Biocontrol Ltd. (APS) Business Overview
- 8.10.3 APS Biocontrol Ltd. (APS) Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.10.4 APS Biocontrol Ltd. (APS) Bacteriophage Product Portfolio
- 8.10.5 APS Biocontrol Ltd. (APS) Recent Developments
- 8.11 Qingdao Phagepharm Bio-tech
- 8.11.1 Qingdao Phagepharm Bio-tech Company Information
- 8.11.2 Qingdao Phagepharm Bio-tech Business Overview
- 8.11.3 Qingdao Phagepharm Bio-tech Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.11.4 Qingdao Phagepharm Bio-tech Bacteriophage Product Portfolio
- 8.11.5 Qingdao Phagepharm Bio-tech Recent Developments
- 8.12 Fixed-Phage Limited
- 8.12.1 Fixed-Phage Limited Company Information
- 8.12.2 Fixed-Phage Limited Business Overview
- 8.12.3 Fixed-Phage Limited Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.12.4 Fixed-Phage Limited Bacteriophage Product Portfolio
- 8.12.5 Fixed-Phage Limited Recent Developments
- 8.13 Zeptometrix
- 8.13.1 Zeptometrix Company Information
- 8.13.2 Zeptometrix Business Overview
- 8.13.3 Zeptometrix Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.13.4 Zeptometrix Bacteriophage Product Portfolio
- 8.13.5 Zeptometrix Recent Developments
- 8.14 Phage International, Inc.
- 8.14.1 Phage International, Inc. Company Information
- 8.14.2 Phage International, Inc. Business Overview
- 8.14.3 Phage International, Inc. Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.14.4 Phage International, Inc. Bacteriophage Product Portfolio
- 8.14.5 Phage International, Inc. Recent Developments
- 8.15 MicroMir
- 8.15.1 MicroMir Company Information
- 8.15.2 MicroMir Business Overview
- 8.15.3 MicroMir Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.15.4 MicroMir Bacteriophage Product Portfolio
- 8.15.5 MicroMir Recent Developments
- 8.16 iNtODEWORLD, Inc.
- 8.16.1 iNtODEWORLD, Inc. Company Information
- 8.16.2 iNtODEWORLD, Inc. Business Overview
- 8.16.3 iNtODEWORLD, Inc. Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.16.4 iNtODEWORLD, Inc. Bacteriophage Product Portfolio
- 8.16.5 iNtODEWORLD, Inc. Recent Developments
- 8.17 NEXTBIOTICS
- 8.17.1 NEXTBIOTICS Company Information
- 8.17.2 NEXTBIOTICS Business Overview
- 8.17.3 NEXTBIOTICS Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.17.4 NEXTBIOTICS Bacteriophage Product Portfolio
- 8.17.5 NEXTBIOTICS Recent Developments
- 8.18 Armata Pharmaceuticals, Inc.
- 8.18.1 Armata Pharmaceuticals, Inc. Company Information
- 8.18.2 Armata Pharmaceuticals, Inc. Business Overview
- 8.18.3 Armata Pharmaceuticals, Inc. Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.18.4 Armata Pharmaceuticals, Inc. Bacteriophage Product Portfolio
- 8.18.5 Armata Pharmaceuticals, Inc. Recent Developments
- 8.19 Innophage
- 8.19.1 Innophage Company Information
- 8.19.2 Innophage Business Overview
- 8.19.3 Innophage Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.19.4 Innophage Bacteriophage Product Portfolio
- 8.19.5 Innophage Recent Developments
- 8.20 Adaptive Phage Therapeutics
- 8.20.1 Adaptive Phage Therapeutics Company Information
- 8.20.2 Adaptive Phage Therapeutics Business Overview
- 8.20.3 Adaptive Phage Therapeutics Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.20.4 Adaptive Phage Therapeutics Bacteriophage Product Portfolio
- 8.20.5 Adaptive Phage Therapeutics Recent Developments
- 8.21 TechnoPhage
- 8.21.1 TechnoPhage Company Information
- 8.21.2 TechnoPhage Business Overview
- 8.21.3 TechnoPhage Bacteriophage Revenue and Gross Margin (2021-2026)
- 8.21.4 TechnoPhage Bacteriophage Product Portfolio
- 8.21.5 TechnoPhage Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst